Dr. Khan will advance Evidation’s leadership in real-world data by driving the clinical strategy for direct-to-participant multimodal data collection to fuel AI-powered discovery and evidence generation.
Evidation, the leader in direct-to-participant real-world data and health research, today announced the appointment of Dr. Ghazanfar Khan as Chief Medical Officer.
A physician and global health leader, Dr. Khan brings deep experience in clinical practice, global public health, digital health innovation, and large-scale multimodal data integration. He joins Evidation as the company continues to expand its leadership in real-world data through its direct, interactive relationship with millions of individuals.
Dr. Khan joins Evidation from Our Future Health, the UK’s largest health research program, where he served as Executive Director of Digital Health and led the integration of multisource health data into population-scale research involving more than a million participants. Previously, he was Head of Clinical at Mendelian, a digital health company accelerating rare disease diagnosis. From 2016 to 2022, Dr. Khan led key global initiatives at the World Health Organization, including the creation of a flagship digital platform that enabled countries to maintain essential health services throughout the COVID-19 pandemic. He was previously appointed as Visiting Scholar and Faculty Affiliate at Harvard Medical School’s Center for Primary Care, where his work focused on the use of patient-generated data in clinical decision-making.
“Dr. Khan’s clinical expertise strengthens Evidation’s ability to build the most context-rich, longitudinal, rigorous real-world data assets in the world,” said Leslie Oley Wilberforce, Chief Executive Officer of Evidation. “By connecting clinical, functional, digital, and biological measures, we’re building a multimodal data foundation that uniquely enables AI-powered discovery and longitudinal evidence generation.”
As Chief Medical Officer, Dr. Khan will lead Evidation’s medical and scientific strategy across the company’s more than 20 active, condition-specific cohorts—longitudinal groups of individuals who share their permissioned data and experiences over time. He will continue to enhance Evidation’s strategy around multimodal data collection, participant experience, and therapeutic area focus to maximize the clinical relevance and scientific impact of person-centered data collection, accelerating innovation and strengthening evidence across life sciences.
“Evidation’s approach creates an incredible opportunity for AI-powered discovery,” said Dr. Khan. “By integrating EHR, genomic, and other novel omics data with real-world wearable and ePRO measures, we can build multimodal datasets that simply do not exist today. These unique resources will unlock entirely new insights into health and disease, enabling us to anticipate changes earlier and drive better outcomes for patients.”
Explore AITechPark for the latest advancements in AI, IOT, Cybersecurity, AITech News, and insightful updates from industry experts!